Objective Antinuclear antibodies (ANAs) are detected in∼ 18% of females, yet autoimmune
disease develops in only 5–8%. Immunologic differences between ANA‐positive healthy …

Background Autoimmune diseases comprise a spectrum of illnesses and are on the rise
worldwide. Although antinuclear antibodies (ANAs) are detected in many autoimmune …

Antinuclear antibodies (ANAs) are venerable biomarkers for assessing the diagnosis and
prognosis of patients with autoimmunity. While closely associated with diseases such as …

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by
antinuclear antibody (ANA) production. ANAs bind to DNA, RNA and complexes of proteins …

Introduction The finding of antinuclear antibody (ANA) positivity in a healthy individual is
usually of unknown significance and in most cases is benign. However, a subset of such …

Objective Growing evidence suggests increasing frequencies of autoimmunity and
autoimmune diseases, but findings are limited by the lack of systematic data and evolving …

Purpose. This study evaluates high‐throughput autoantibody screening and determines
associated systemic lupus erythematosus (SLE) clinical features in a large lupus cohort …

Objective. Growing evidence suggests increasing frequencies of autoimmunity and certain
autoimmune diseases, but findings are limited by the lack of systematic data and evolving …

Objective To estimate the prevalence, types, and sociodemographic and biobehavioral
correlates of antinuclear antibodies (ANAs) in the US. Methods We conducted a cross …

The objective of this study was to determine the prevalence of lupus-related autoimmunity in
a community-based cohort of over 3000 subjects, using a rheumatology registry as a …